Prognosis
Roche CEO Seeks High-Risk, High-Reward Drugs to 'Deliver Value Fast'
- Drugmaker aims to move fast on high-risk, high-reward projects
- Swiss company slipped from top spot in oncology to third
This article is for subscribers only.
Roche Holding AG will push for a more productive pipeline of new medicines as a new management team seeks to learn the lessons from recent research setbacks.
The company aims to move fast on high-risk, high-reward projects, Chief Executive Officer Thomas Schinecker said at a meeting with analysts and investors in London. Roche will also seek deals, he said, looking at potential targets that are already in human trials, typically a pricier class of assets.